<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24444522</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Mauricio, DÃ­dac</dc:author>
<dc:description xml:lang="en">The therapeutic armamentarium for the treatment of hyperglycemia in type 2 diabetes mellitus is still inadequate. We are currently witnessing the introduction of a new mode of hypoglycemic treatment through induction of glycosuria to decrease the availability of the metabolic substrate, i.e. glucose. Clinical trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors are as efficacious as other oral hypoglycemic drugs. This article discusses the basic features of this new treatment concept and the efficacy and safety of this new drug group.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:subject>Glycosuria</dc:subject>
<dc:subject>Type 2 sodium/glucose co-transporter inhibitors</dc:subject>
<dc:subject>Diabetes mellitus tipo 2</dc:subject>
<dc:subject>Seguridad</dc:subject>
<dc:subject>Inhibidores del cotransportador sodio/glucosa tipo 2</dc:subject>
<dc:subject>Efficacy</dc:subject>
<dc:subject>Glucosuria</dc:subject>
<dc:subject>Safety</dc:subject>
<dc:subject>Type 2 diabetes mellitus</dc:subject>
<dc:subject>Eficacia</dc:subject>
<dc:date>2013 Sep </dc:date>
<dc:title xml:lang="es">Inhibidores SGLT-2: de la corteza del manzano y la glucosuria familiar al tratamiento de la diabetes mellitus tipo 2.</dc:title>
<dc:title xml:lang="en">[Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
